Hemodynamic Response to Laryngoscopy and Tracheal IntubationNCT07793955
Intravenous Magnesium Sulphate Versus Lignocaine for Attenuating Hemodynamic Responses to Laryngoscopy and Endotracheal Intubation
A study testing Magnesium Sulphate infusion in people with Hemodynamic Response to Laryngoscopy and Tracheal Intubation, run by Lady Reading Hospital, Pakistan.
Trial summary
This study will compare intravenous magnesium sulfate with intravenous lidocaine for reducing the cardiovascular response to endotracheal intubation in adult patients undergoing general anesthesia. Eligible participants will receive either magnesium sulfate or lidocaine before endotracheal intubation. Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Hemodynamic Response to Laryngoscopy and Tracheal Intubation
- What is being tested?
- Magnesium Sulphate infusion
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 78 participants
- Where
- No sites listed yet
- Study dates
- 20 Aug 2026to 20 Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- age 18-70 yrs
- male and female patients
- patients undergoing elective or emergency procedures under general anesthesia
Who cannot join
- pregnancy
- anticipated difficult airway
About this study
Official title: Comparison of Intravenous Magnesium Sulphate and Lignocaine in Attenuation of Hemodynamic Responses to Laryngoscopy and Endotracheal Intubation
This study will compare intravenous magnesium sulfate with intravenous lidocaine for reducing the cardiovascular response to endotracheal intubation in adult patients undergoing general anesthesia. Eligible participants will receive either magnesium sulfate or lidocaine before endotracheal intubation. Heart rate and blood pressure will be recorded at predefined time points before and after intubation to compare the effectiveness of the two interventions in attenuating the hemodynamic response to laryngoscopy and endotracheal intubation.
- Being tested
- Magnesium Sulphate infusion
- Keywords
- magnesium suplhate, lignocaine, endotracheal intubation, hemodynamic response, laryngoscopy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Magnesium Sulphate infusionDrug
intravenous magnesium Sulphate 30mg /kg diluted in 100ml normal saline, administered 90 sec before induction of general anesthesia
| Study group | Role | What they receive |
|---|---|---|
| intravenous Magnesiumm sulphate | Experimental | participants will receive intravenous magnesium Sulphate 30mg/kg diluted in 100ml normal saline ,administered 90 seconds before induction of general anesthesia Receives: Drug: Magnesium Sulphate infusion |
| intravenous lignocaine | Active comparator | participants will receive intravenous lignocaine 2mg/kg ,administered 90 seconds before induction of general anesthesia Receives: Drug: Magnesium Sulphate infusion |
What is being measured
The primary outcome is the main question the study is designed to answer.
heart rate 5minutes after endotracheal intubation
Measured: 5 minutes after endotracheal intubation
systolic blood pressure 5 minutes after endo tracheal intubation
Measured: 5 minutes after endotracheal intubation
mean arterial pressure 5 minutes after endotracheal intubation
Measured: 5 minutes after endotracheal intubation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Aug 2026
- Study start20 Aug 2026 (estimated)
- Primary completion20 Sep 2026 (estimated)
- Study completion20 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hemodynamic Response to Laryngoscopy and Tracheal IntubationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 78 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Lady Reading Hospital, Pakistan
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Syed Muhtaram Shah, Lady Reading Hospital, Pakistan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07793955
- Sponsor's protocol ID
- ANS-2023-022-3243
- Other IDs
- 416/LRH/MTI
- Status last verified
- Sep 2026
- First submitted
- 25 Aug 2026
- Last updated
- 8 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Intravenous Magnesium Sulphate and Lignocaine in Attenuation of Hemodynamic Responses to Laryngoscopy and Endotracheal Intubation
- ClinicalTrials.gov ID
- NCT07793955
- Acronym / sponsor ID
- ANS-2023-022-3243
- Keywords
- magnesium suplhate, lignocaine, endotracheal intubation, hemodynamic response, laryngoscopy
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 78 participants (estimated)
- Lead sponsor
- Lady Reading Hospital, PakistanOther government
- Study start
- 20 Aug 2026 (estimated)
- Primary completion
- 20 Sep 2026 (estimated)
- Study completion
- 20 Sep 2026 (estimated)
- First posted
- 31 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will compare intravenous magnesium sulfate with intravenous lidocaine for reducing the cardiovascular response to endotracheal intubation in adult patients undergoing general anesthesia. Eligible participants will receive either magnesium sulfate or lidocaine before endotracheal intubation. Heart rate and blood pressure will be recorded at predefined time points before and after intubation to compare the effectiveness of the two interventions in attenuating the hemodynamic response to laryngoscopy and endotracheal intubation.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| intravenous Magnesiumm sulphate | Experimental | Drug: Magnesium Sulphate infusionparticipants will receive intravenous magnesium Sulphate 30mg/kg diluted in 100ml normal saline ,administered 90 seconds before induction of general anesthesia |
| intravenous lignocaine | Active comparator | Drug: Magnesium Sulphate infusionparticipants will receive intravenous lignocaine 2mg/kg ,administered 90 seconds before induction of general anesthesia |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- age 18-70 yrs
- male and female patients
- patients undergoing elective or emergency procedures under general anesthesia
Key exclusion criteria (2 listed)
- pregnancy
- anticipated difficult airway
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Magnesium Sulphate infusionintravenous magnesium Sulphate 30mg /kg diluted in 100ml normal saline, administered 90 sec before induction of general anesthesia | Drug | intravenous Magnesiumm sulphate, intravenous lignocaine |
Primary outcome
heart rate 5minutes after endotracheal intubation
Time frame: 5 minutes after endotracheal intubation
systolic blood pressure 5 minutes after endo tracheal intubation
Time frame: 5 minutes after endotracheal intubation
mean arterial pressure 5 minutes after endotracheal intubation
Time frame: 5 minutes after endotracheal intubation
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Sep 2026.
Related trials for Hemodynamic Response to Laryngoscopy and Tracheal Intubation
Not yet recruiting
Hemodynamic Responses to Laryngoscopy and Tracheal Intubation
Hemodynamic Response to Laryngoscopy and Tracheal Intubation
Not yet recruitingPhase 2/3
Oral Melatonin VS Nebulized Dexmedetomidine Premedication on Attenuation of Hemodynamic Response to Direct Laryngoscopy and Tracheal Intubation in Hypertensive Patients
Tracheal Intubation Morbidity, Laryngoscopy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Magnesium Sulphate infusion in people with Hemodynamic Response to Laryngoscopy and Tracheal Intubation, run by Lady Reading Hospital, Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 8 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
heart rate 5minutes after endotracheal intubation (time frame: 5 minutes after endotracheal intubation). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2026; AzTrials last refreshed its copy on 8 Nov 2026.